Actuate Therapeutics Inc carries a market capitalization of 44.50M, placing it among publicly traded companies globally.
| Market Cap | 44.50M |
| Enterprise Value | N/A |
Actuate Therapeutics Inc currently has 23.71M shares outstanding.
| Shares Outstanding | 23.71M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.37 |
| P/TBV Ratio | 15.59 |
| P/FCF Ratio | -3.01 |
| P/OCF Ratio | -3.01 |
Actuate Therapeutics Inc maintains a current ratio of 1.80, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.80 |
| Quick Ratio | 1.72 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,078.36 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -321.58 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Actuate Therapeutics Inc's stock has declined approximately -80.92308% over the past 52 weeks. The 50-day moving average sits at 2.48, while the 200-day moving average is 5.21.
| Beta (5Y) | N/A |
| 52-Week Price Change | -80.92308% |
| 50-Day Moving Average | 2.48 |
| 200-Day Moving Average | 5.21 |
| Average Volume (20 Days) | N/A |
EBITDA reached -21.84M, while operating income came in at -21.84M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -21.84M |
| Pretax Income | -21.54M |
| Net Income | -21.54M |
| EBITDA | -21.84M |
| EBIT | -21.84M |
| Earnings Per Share (EPS) | -1.00 |
Total book value stands at -160.23M, with working capital of 3.80M providing operational flexibility.
| Cash & Cash Equivalents | 8.13M |
| Total Debt | N/A |
| Net Debt | -8.13M |
| Equity (Book Value) | -160.23M |
| Book Value Per Share | -7.44 |
| Working Capital | 3.80M |
Actuate Therapeutics Inc produced -19.60M in operating cash flow over the past twelve months.
| Operating Cash Flow | -19.60M |
| Capital Expenditures | N/A |
| Free Cash Flow | -19.60M |
| FCF Per Share | -0.91 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -40.44 |
| FCF Yield | -33.24 |
Actuate Therapeutics Inc posts an Altman Z-Score of -25.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -25.85 |